July 2016 - Page 2 of 2 - Buhlmann Diagnostics Corp

Month: July 2016

Comparison of Six Different Calprotectin Assays for the Assessment of Inflammatory Bowel Disease

Quantum Blue® fCAL Citation Labaere, D, Smismans A, Olmen A, Christiaens P, D’Haens G, Moons V, Cuyle P, Frans J, and Bossuyt P. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease, United European Gastroenterology J. 2014 Feb; 2(1): 30–37.  doi:  10.1177/2050640613518201 Highlight from this Publication "The EliA [Phadia] cut off for diagnosis was optimal at a level of 15 mg/g. This
Continue Reading

Fecal Calprotectin: Towards a Standardized Use for Inflammatory Bowel Disease Management in Routine Practice

Value of Fecal Calprotectin in the Diagnosis of IBD: Edouard, Louis. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. Journal of Crohn's and Colitis, 2015, 1–3 doi:10.1093/ecco-jcc/jju012. “…fecal calprotectin as a unique first line test would be sufficient to decide in which patient to perform further endoscopic or medical imaging
Continue Reading

Flow CAST® eBook- Kinase Inhibition Assay for BTK, SYK, and PI3K Activity

Flow CAST® eBook Testing Potency and Efficacy of Inhibitors of PI3K, PI3K, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, SYK and BTK pathways are a large focus for pharmaceutical companies with several
Continue Reading

A New Rapid Quantitative Test for Fecal Calprotectin Predicts Endoscopic Activity in Ulcerative Colitis

Quantum Blue®  fCAL Citation Lobatón T, Rodríguez-Moranta F, Lopez A, Sánchez E, Rodríguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis.   Inflamm Bowel Dis. 2013 Apr;19(5):1034-42. doi: 10.1097/MIB.0b013e3182802b6e. PMID: 23470502 Highlight from this Publication “FC determined by QPOCT was an accurate surrogate marker of “endoscopic remission”
Continue Reading

Other BÜHLMANN Fecal Calprotectin Assays Citations

Wright, E.K. et al., Cost-effectiveness of Crohn’s disease post-operative care, World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860. Shentova, R. et al., 2016, Diagnostic Value of Fecal Calprotectin Point of Care Testing in the Pediatric Practice, Merit Res. J. Med. Med. Sci. Available online http://www.meritresearchjournals.org/mms/index.htm Gauss, A. et al., Quality of Life Is Related to

Continue Reading